IRON insider ownership: who sold, why, and what they still hold

What stands out

Kevin Bitterman sold $2.5M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Sep 11, 2026

Outside holders and shareholders represented on the board, not part of management, sold heavily: AI DMI LLC ($59.9M) and Kevin Bitterman ($28.8M).AI DMI LLC: largest sale, Oct 22, 2025 · Kevin Bitterman: largest sale, Dec 16, 2025

A share of stake is shown for 0 of the 7 officers and directors who sold. 14 are left out

Left out: Mona Ashiya, John Quisel, William Savage, Pamela Stephenson, Jean Franchi, Jonathan Yu, Rahul Khara, Georges Gemayel, William White, Mark Chin, Liam Ratcliffe, Donald Nicholson, Kevin Bitterman and Nadim Ahmed (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

John Quisel

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$12.0M93% planned, 7% to cover taxes

Jonathan Yu

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.6M96% planned, 4% to cover taxes

Kevin Bitterman

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.5MNo plan disclosed

William Savage

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.3M91% planned, 9% to cover taxes

Rahul Khara

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.9M90% planned, 10% to cover taxes

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 11, 2026Kevin Bitterman sold 27K shares ($1.9M) with no plan disclosed. 27K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Kevin Bitterman Director	27,136	$70.11	n/a	n/a	Sep 11, 2026	Sep 15, 2026

Outside holders, reported separately

AI DMI LLC sold $59.9M and Kevin Bitterman (for the outside shareholder represented on the board) sold $28.8M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Disc Medicine, Inc. CEO selling stock?

Yes. John Quisel sold 153K shares ($12.0M) in the past 12 months, 93% of it under a trading plan disclosed in the filings.

Why are Disc Medicine, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 83% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 7% were to cover taxes and 10% had no disclosed plan. A trading plan schedules sales in advance.

Are any Disc Medicine, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
John Quisel Chief Executive Officer, Director	$12.0M 153K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes
Jonathan Yu Chief Operating Officer	$5.6M 72K shares	Not confirmed share of stake is being verified. Why	96% under a disclosed plan, 4% to cover taxes
Kevin Bitterman Director	$2.5M 34K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
William Savage Chief Medical Officer	$2.3M 29K shares	Not confirmed share of stake is being verified. Why	91% under a disclosed plan, 9% to cover taxes
Rahul Khara Chief Legal Officer	$1.9M 25K shares	Not confirmed share of stake is being verified. Why	90% under a disclosed plan, 10% to cover taxes
Jean Franchi Chief Financial Officer	$1.2M 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Pamela Stephenson Chief Commercial Officer	$348K 5.5K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Board members representing outside shareholders, reported separately: Kevin Bitterman (the shareholder sold $28.8M), Mona Ashiya. Details

Outside holder, reported separately: AI DMI LLC (a 10% owner, not part of management). Sold $59.9M (744K shares) from Oct 22, 2025 to Oct 22, 2025. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Mona Ashiya

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mona Ashiya are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Mona Ashiya

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mona Ashiya are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

John Quisel

Chief Executive Officer, Director

n/a

−153K

n/a

Vesting, gifts, unvested awards and holding lines for John Quisel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Quisel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
150,120	$1.01	Mar 10, 2030	$10.4M
41,830	$2.65	Oct 22, 2030	$2.8M
15,791	$9.86	Sep 13, 2031	$951K
91,586	$13.50	Dec 28, 2032	$5.2M
99,550	$63.90	Jan 9, 2034	$618K
117,505	$54.71	Feb 9, 2035	$1.8M
82,800	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

William Savage

Chief Medical Officer

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for William Savage

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Savage are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,550	$9.86	Sep 13, 2031	$214K
2,628	$9.86	Sep 13, 2031	$158K
29,905	$13.50	Dec 28, 2032	$1.7M
27,800	$63.90	Jan 9, 2034	$173K
36,000	$54.71	Feb 9, 2035	$554K
25,500	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Pamela Stephenson

Chief Commercial Officer

n/a

−5.5K

n/a

Vesting, gifts, unvested awards and holding lines for Pamela Stephenson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Pamela Stephenson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
55,000	$64.66	Feb 25, 2034	$300K
36,000	$54.71	Feb 9, 2035	$554K
25,500	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Jean Franchi

Chief Financial Officer

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Jean Franchi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean Franchi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
55,000	$65.25	Feb 6, 2034	$267K
36,000	$54.71	Feb 9, 2035	$554K
25,500	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Jonathan Yu

Chief Operating Officer

n/a

−72K

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Yu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Yu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,941	$2.65	Aug 10, 2030	$536K
1,753	$9.86	Sep 13, 2031	$106K
31,951	$9.86	Sep 13, 2031	$1.9M
13,847	$13.50	Dec 28, 2032	$784K
27,250	$63.90	Jan 9, 2034	$169K
36,000	$54.71	Feb 9, 2035	$554K
25,500	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Rahul Khara

Chief Legal Officer

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Rahul Khara

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rahul Khara are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
49,804	$14.69	Feb 6, 2032	$2.8M
21,270	$13.50	Dec 28, 2032	$1.2M
21,050	$63.90	Jan 9, 2034	$131K
36,000	$54.71	Feb 9, 2035	$554K
25,500	$74.75	Feb 9, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Georges Gemayel

Director

n/a

Vesting, gifts, unvested awards and holding lines for Georges Gemayel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Georges Gemayel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K
1,000	$60.34	Sep 15, 2035	$10K
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

William White

Director

n/a

Vesting, gifts, unvested awards and holding lines for William White

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William White are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,804	$9.86	Sep 13, 2031	$109K
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Mark Chin

Director

n/a

Vesting, gifts, unvested awards and holding lines for Mark Chin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Chin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Liam Ratcliffe

Director

n/a

Vesting, gifts, unvested awards and holding lines for Liam Ratcliffe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Liam Ratcliffe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Donald Nicholson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Donald Nicholson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Donald Nicholson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$38.85	Jun 11, 2034	$313K
10,000	$50.86	Jun 10, 2035	$193K
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Kevin Bitterman

Director

n/a

−34K

n/a

Vesting, gifts, unvested awards and holding lines for Kevin Bitterman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Bitterman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,212	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Nadim Ahmed

Director

n/a

Vesting, gifts, unvested awards and holding lines for Nadim Ahmed

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nadim Ahmed are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,000	$57.74	Jul 13, 2035	$247K
5,176	$70.79	Jun 17, 2036	$0

Estimate: options held × ($70.11 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Holdings and share of stake for Disc Medicine, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$25.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $25.9M across 337,751 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $21.5M · 83%

17%

The lighter segment is sales with no plan disclosed in the filing ($4.3M), including tax-related sales outside a plan.

No plan disclosed · $2.5M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.5M of it is Kevin Bitterman. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Kevin Bitterman, Sep 11, 2026

Taxes

$2.0M of sales (7.8%) cite tax obligations in their footnotes, $256K of them also under a plan. Example: Rahul Khara, Feb 17, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
John Quisel Chief Executive Officer, Director	153K	$12.0M	93%	47%	Dec 11, 2025 to Aug 17, 2026
Jonathan Yu Chief Operating Officer	72K	$5.6M	96%	22%	Nov 11, 2025 to Aug 25, 2026
Kevin Bitterman Director	34K	$2.5M	0%	10%	Dec 15, 2025 to Sep 11, 2026
William Savage Chief Medical Officer	29K	$2.3M	91%	9%	Dec 15, 2025 to Apr 13, 2026
Rahul Khara Chief Legal Officer	25K	$1.9M	90%	7%	Jan 2, 2026 to Aug 6, 2026
Jean Franchi Chief Financial Officer	18K	$1.2M	100%	5%	Feb 17, 2026 to Apr 14, 2026
Pamela Stephenson Chief Commercial Officer	5.5K	$348K	0%	1%	Feb 17, 2026 to Feb 17, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$2.5M	$2.5M	$0	$0
Dec 2025	$5.6M	$4.9M	$0	$643K
Jan 2026	$581K	$581K	$0	$0
Feb 2026	$2.5M	$744K	$1.8M	$0
Mar 2026	$486K	$486K	$0	$0
Apr 2026	$841K	$841K	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$5.1M	$5.1M	$0	$0
Jul 2026	$2.5M	$2.5M	$0	$0
Aug 2026	$3.8M	$3.8M	$0	$0
Sep 2026	$1.9M	$0	$0	$1.9M
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Kevin Bitterman ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kevin Bitterman are complete. Director	n/a	−328K	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Kevin Bitterman Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Bitterman are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)
Mona Ashiya ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mona Ashiya are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Mona Ashiya Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mona Ashiya are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $25.9M sold, after almost none in the past 5 years. 7 insiders sold; the average is 3 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	338K	7	$25.9M
Oct 13, 2025 1 year earlier	167K	7	$9.8M
Oct 13, 2024 2 years earlier	66K	5	$3.7M
Oct 14, 2023 3 years earlier	50K	3	$2.5M
Oct 14, 2022 4 years earlier	0	0	$0
Oct 14, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Disc Medicine, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology281 filings on record, 50 filed in the 12-month period, and how we read them

All 281 Forms 3, 4 and 5 on record for Disc Medicine, Inc. (SEC CIK 1816736), filed from Aug 11, 2020 to Sep 16, 2026; 50 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (29)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
ORBIMED ADVISORS LLC	Mar 26, 2025	1,415,020 shares, last reported balance as of Mar 24, 2025
Joanne Bryce	Mar 1, 2024	23,665 shares, last reported balance as of Jan 10, 2024
Atlas Venture Fund X, L.P.	Jan 25, 2024	2,304,172 shares, last reported balance as of Jan 23, 2024
Brian MacDonald	Jun 30, 2023	15,564 shares, last reported balance as of Jun 30, 2023
Novo Holdings A/S	Jun 28, 2023	1,090,772 shares, last reported balance as of Jun 28, 2023
Jay Backstrom	Jan 3, 2023	No balance on record
Braden Leonard	Oct 27, 2022	5,247,500 shares, last reported balance as of Oct 26, 2022
Brian Piekos	Jun 2, 2022	17,615 shares, last reported balance as of May 31, 2022
David Lubner	Mar 9, 2022	No balance on record
Tuyen Ong	Mar 9, 2022	No balance on record
Jason Meyenburg	Jan 5, 2022	13,000 shares, last reported balance as of May 14, 2021
James Tananbaum	Oct 6, 2021	14,689,500 shares, last reported balance as of Oct 4, 2021
Carl Gordon	Oct 6, 2021	5,826,224 shares, last reported balance as of Feb 5, 2021
Jason Rhodes	Oct 6, 2021	4,744,365 shares, last reported balance as of Feb 5, 2021
Jason Rhodes	Oct 6, 2021	510,000 shares, last reported balance as of Feb 5, 2021
Walter Strapps	May 3, 2021	No balance on record
Samuel Barone	Apr 14, 2021	No balance on record
Scott Lauder	Apr 7, 2021	104,622 shares, last reported balance as of Feb 5, 2021
Precillia Redmond	Apr 7, 2021	No balance on record
Marc Uknis	Apr 7, 2021	No balance on record
LSV Associates, LLC	Feb 16, 2021	4,836,106 shares, last reported balance as of Feb 5, 2021
Jean George	Feb 16, 2021	4,836,106 shares, last reported balance as of Feb 5, 2021
Gregg Beloff	Feb 10, 2021	No balance on record
Robert Carey	Aug 11, 2020	30,000 shares, last reported balance as of Aug 11, 2020
Daniel Dubin	Aug 11, 2020	30,000 shares, last reported balance as of Aug 11, 2020
Deepika Pakianathan	Aug 11, 2020	30,000 shares, last reported balance as of Aug 11, 2020
Dennis Ryan		No balance on record
Michael Rome		No balance on record
Vikram Bajaj		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Disc Medicine, Inc. insiders sold $25.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Disc Medicine, Inc. CEO selling stock?

Why are Disc Medicine, Inc. insiders selling?

Are any Disc Medicine, Inc. insiders buying?

The evidence

No plan disclosed · $2.5M

Taxes

Sales by month